Puma Biotechnology (PBYI) Profit After Tax (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Profit After Tax data on file, last reported at -$3.8 million in Q1 2026.

• Quarterly Profit After Tax fell 226.19% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.4 million (down 35.94% YoY) and the FY2025 annual result came in at $31.1 million, up 2.75% from the prior year.
• Profit After Tax slipped to -$3.8 million in Q1 2026, from $13.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $20.3 million in Q3 2024 to a low of -$5.6 million in Q4 2022.
• A 5-year average of $4.7 million and a median of $3.0 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax surged 1710.0% — and 2024, when it slumped 443.68%.
• Tracing PBYI's Profit After Tax over 5 years: stood at -$5.6 million in 2022, then soared by 318.84% to $12.3 million in 2023, then jumped by 57.36% to $19.3 million in 2024, then plunged by 30.39% to $13.4 million in 2025, then slumped by 127.93% to -$3.8 million in 2026.
• The last three Profit After Tax figures came in at -$3.8 million (Q1 2026), $13.4 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.